No Data
No Data
Hunan Hansen Pharmaceutical: Half-year report for the year 2024.
Hunan Hansen Pharmaceutical: Summary of Half-Year Report in 2024.
Hunan Hansen Pharmaceutical (002412.SZ): net income in the first half of the year was 0.1 billion yuan, a year-on-year increase of 10.84%.
On August 13th, Gelunhui announced that the half-year report of Hunan Hansen Pharmaceutical (002412.SZ) showed that the company achieved a total operating revenue of 480.4458 million yuan, a year-on-year increase of 1.86%; a total profit of 115.8673 million yuan, a year-on-year increase of 15.70%; and a net income of 100.494 million yuan attributable to shareholders of the listed company, a year-on-year increase of 10.84%. The company has established a good reputation and a good user base through many years of operation, has a nationally certified green factory, and has a leading intelligent manufacturing production line. The company was recognized as being located in Hunan province during the reporting period.
Hunan Hansen Pharmaceutical (002412.SZ): Pharmaceutical production license changed with new production scope of "Class II Psychotropic Drugs (Hydrobromide R-Mephenytoin Granules)".
On August 8th, Gelunhui reported that Hunan Hansen Pharmaceutical (002412.SZ) has recently completed the change registration of the Pharmaceutical Production License and obtained the Pharmaceutical Production License issued by the Hunan Provincial Drug Administration. The scope of production has been added to include the production of the second-class psychotropic drug (hydrobromide right-methylmorpholine granules). Other content remains unchanged.
Hunan Hansen Pharmaceutical's Gets Nod to Make Changes to Iopamidol Injection
Hanson Pharmaceuticals (002412.SZ): The company's planting site has not yet planted Baishu
Gelonghui May 16 | Hanson Pharmaceuticals (002412.SZ) said on the investor interactive platform that the company's planting site has not yet planted Baishu.
No Data
No Data